

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

1. **PARTIAL EARLY REDEMPTION OF CONVERTIBLE BONDS**
 2. **AMENDMENT DEED TO TERMS AND CONDITIONS OF CONVERTIBLE BONDS**
-

*Unless otherwise defined, capitalised terms used herein shall bear the same meanings ascribed to them in the Company's announcements dated 31 January 2019, 8 February 2019, 26 February 2019, 8 March 2019, 25 April 2019, 17 May 2019, 1 August 2019 and 15 August 2019 in relation to the Convertible Bonds ("**Announcements**").*

1. **PARTIAL EARLY REDEMPTION OF CONVERTIBLE BONDS**

Further to the Announcements, the Board wishes to announce that the Company had, today, issued notice to the holders of the Convertible Bonds ("**Bondholders**") pursuant to which the Company shall partially redeem on a *pro rata* basis S\$3,525,000 in principal amount of the Convertible Bonds on 8 October 2021 in accordance with the terms and conditions of the Convertible Bonds (the "**Partial Early Redemption**"). The Partial Early Redemption will be funded from internal resources of the Group.

As at the date of this announcement, the outstanding principal amounts of the Series 1 Convertible Bonds and the Series 2 Convertible Bonds is S\$5,550,000 and S\$1,500,000 respectively. Following the completion of the Partial Early Redemption, the principal amounts of the Series 1 Convertible Bonds and the Series 2 Convertible Bonds that remain outstanding shall be S\$2,775,000 and S\$750,000 respectively (each the "**Outstanding Series 1 Convertible Bonds**" and the "**Outstanding Series 2 Convertible Bonds**", and collectively, the "**Outstanding Convertible Bonds**"). Based on the Adjusted Conversion Price of S\$0.14, up to 25,178,571 Conversion Shares will be allotted and issued by the Company upon the conversion of all the Outstanding Convertible Bonds.

2. **AMENDMENT DEED TO TERMS AND CONDITIONS OF CONVERTIBLE BONDS**

The Company and the Bondholders had also today, entered into an amendment deed (the "**Amendment Deed**") to amend certain terms and conditions of the Convertible Bonds, including but not limited to:

- (i) vary the denomination of the Convertible Bonds from S\$50,000 to S\$25,000 to facilitate the Partial Early Redemption and the reduced holdings of the Bondholders upon completion of the Partial Early Redemption, and
- (ii) to extend the Maturity Date of the Outstanding Convertible Bonds for a further two (2) years, conditional upon completion of the Partial Early Redemption (the "**Extension**").

Accordingly, upon the completion of the Partial Early Redemption, the Maturity Date of the Series 1 Outstanding Convertible Bonds and the Series 2 Outstanding Convertible Bonds shall be 8 March 2024 and 17 May 2024 respectively.

3. RATIONALE FOR THE PARTIAL EARLY REDEMPTION AND THE EXTENSION

The Board is of the view that the Partial Early Redemption and the Extension are in the best interests of the Group as the Partial Early Redemption allows the Group to reduce its interest payment obligations arising from the Convertible Bonds, while the Extension provides financial flexibility to the Group for expansion of its business, which may be undertaken by way of organic growth or through investments, joint ventures, strategic collaborations, and mergers and acquisitions.

4. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

Save for Yee Pinh Jeremy and Chen Johnson, who are holders of the Convertible Bonds, none of the Directors, and as far as the Directors are aware, none of the substantial shareholders of the Company or any of their respective associates, has any interest, direct or indirect, in the Partial Early Redemption and the Amendment Deed, other than through their respective shareholding interests in the Company (if any).

5. DOCUMENT AVAILABLE FOR INSPECTION

A copy of the Amendment Deed is available for inspection from 9.00 a.m. to 5.30 p.m.¹ at the registered address of the Company for a period of three (3) months from the date of this announcement.

BY ORDER OF THE BOARD

Andrew John Lord
Lead Independent Director

17 September 2021

This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.

¹ Prior appointment with the Company is required. Please contact the Company's Investor Relations team at +65 6251 0136 or email: contactus@clearbridgehealth.com.